HighPoint Advisor Group LLC Sells 25,455 Shares of Kenvue Inc. (NYSE:KVUE)

HighPoint Advisor Group LLC trimmed its position in Kenvue Inc. (NYSE:KVUE - Free Report) by 29.4% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 61,153 shares of the company's stock after selling 25,455 shares during the quarter. HighPoint Advisor Group LLC's holdings in Kenvue were worth $1,430,000 at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in the company. Fulton Bank N.A. boosted its position in Kenvue by 0.6% in the first quarter. Fulton Bank N.A. now owns 78,888 shares of the company's stock valued at $1,892,000 after buying an additional 465 shares in the last quarter. Scott & Selber Inc. boosted its position in Kenvue by 0.4% in the first quarter. Scott & Selber Inc. now owns 106,621 shares of the company's stock valued at $2,557,000 after buying an additional 475 shares in the last quarter. Wealth Alliance LLC lifted its holdings in shares of Kenvue by 1.6% during the first quarter. Wealth Alliance LLC now owns 31,778 shares of the company's stock worth $762,000 after purchasing an additional 486 shares during the period. Keystone Financial Group lifted its holdings in shares of Kenvue by 4.8% during the fourth quarter. Keystone Financial Group now owns 12,736 shares of the company's stock worth $272,000 after purchasing an additional 578 shares during the period. Finally, Transatlantique Private Wealth LLC lifted its holdings in shares of Kenvue by 5.7% during the fourth quarter. Transatlantique Private Wealth LLC now owns 10,680 shares of the company's stock worth $228,000 after purchasing an additional 580 shares during the period. 97.64% of the stock is owned by institutional investors.

Kenvue Trading Down 0.2%

NYSE KVUE traded down $0.06 during mid-day trading on Friday, reaching $22.45. 1,697,599 shares of the stock were exchanged, compared to its average volume of 17,164,723. Kenvue Inc. has a one year low of $18.10 and a one year high of $25.17. The company has a debt-to-equity ratio of 0.63, a current ratio of 0.86 and a quick ratio of 0.60. The stock has a market cap of $43.07 billion, a P/E ratio of 40.79, a P/E/G ratio of 3.76 and a beta of 0.83. The stock has a 50 day simple moving average of $22.05 and a 200-day simple moving average of $22.33.

Kenvue (NYSE:KVUE - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported $0.24 earnings per share for the quarter, beating the consensus estimate of $0.23 by $0.01. Kenvue had a net margin of 6.90% and a return on equity of 20.87%. The firm had revenue of $3.74 billion during the quarter, compared to the consensus estimate of $3.69 billion. During the same period in the previous year, the firm posted $0.28 earnings per share. The business's revenue was down 3.9% compared to the same quarter last year. On average, analysts anticipate that Kenvue Inc. will post 1.14 EPS for the current year.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the stock. Citigroup cut their price target on shares of Kenvue from $24.50 to $22.00 and set a "neutral" rating on the stock in a report on Tuesday, July 15th. Barclays cut their price target on shares of Kenvue from $23.00 to $22.00 and set an "equal weight" rating on the stock in a report on Tuesday, July 15th. UBS Group cut their price target on shares of Kenvue from $25.00 to $23.00 and set a "neutral" rating on the stock in a report on Thursday, July 17th. Redburn Atlantic assumed coverage on shares of Kenvue in a report on Thursday, April 10th. They set a "neutral" rating and a $23.50 price target on the stock. Finally, Bank of America cut their price target on shares of Kenvue from $27.00 to $25.00 and set a "buy" rating on the stock in a report on Tuesday, July 15th. Seven analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus target price of $24.71.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.